Monoclonal antibodies and breast cancer. Current therapeutic progress;Anticorps monoclonaux et cancer du sein. Actualités thérapeutiques

Revue Medicale de Liege

Volumn 64, Issue 5-6, 2009, Pages 279-283

  Collignon, J ^a   Gennigens, C ^a   Rorive, A ^a   Coucke, P ^a   Lifrarange, E ^a   Maweja, S ^a   Fillet, G ^a   Jerusalem, G ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bevacizumab; Breast cancer; Targeted therapy; Trastuzumab

Indexed keywords

AMG 386; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CARDIOTOXICITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; METASTASIS; REVIEW; SKIN TOXICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67749084418     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Di Cosimo S, Baselga J.- Targeted therapies in breast cancer: where are we now? Eur J Cancer, 2008, 44, 2781-2790.
2. Oldham RK, Dillman RO.- Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol, 2008, 26, 1774-1777.
3. Orman JS, Perry CM.- Trastuzumab : in HER2 and hormone receptor co-positive metastatic breast cancer. Drugs, 2007, 67, 2781-2789. (Pubitemid 350224384)
4. Izzedine H, Ederhy S, Goldwasser F, et al.- Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol, 2009, 20, 807-815.
5. Hicks DG, Kulkarni S.- Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med, 2008, 132, 1008-1015. (Pubitemid 351918709)
6. Wolff AC, Hammond ME, Schwartz JN, et al.- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med, 2007, 131, 18. (Pubitemid 46174133)
7. Bono P, Elfving H, Utriainen T, et al.- Hypertension and clinical benefit of bévacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol, 2009, 20, 393-394.
8. Bartsch R, Wenzel C, Altorjai G, et al.- Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol, 2007, 25, 3853-3858. (Pubitemid 47477260)
9. Bullock K, Blackwell K.- Clinical efficacy of taxanetrastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist, 2008, 13, 515-525. (Pubitemid 351872869)
10. Jahanzeb M.- Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer, 2008, 8, 324-333.
11. Untch M, Gelber RD, Jackisch C, et al.- Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol, 2008, 19, 1090-1096. (Pubitemid 351796334)
12. Wildiers H, Kunkler I, Biganzoli L, et al.- Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol, 2007, 8, 1101-1115. (Pubitemid 350182967)
13. Dinh P, de Azambuja E, Cardoso F, Piccart-Gebhart MJ.- Facts and controversies in the use of trastuzumab in the adjuvant setting. Nat Clin Pract Oncol, 2008, 5, 645-654.
14. Lazaridis G, Pentheroudakis G, Pavlidis N.- Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol, 2008, 66, 31-41. (Pubitemid 351324127)
15. Dawood S, Broglio K, Esteva FJ, et al.- Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol, 2008, 19, 1242-1248. (Pubitemid 351911952)
16. Madarnas Y, Trudeau M, Franek JA, et al.- Adjuvant/ neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev, 2008, 34, 539-557.
17. Folkman J.- Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971, 285, 1182-1186.
18. Bando H.- Vascular endothelial growth factor and bevacitumab in breast cancer. Breast Cancer, 2007, 14, 163-173.
19. Van Cutsem E, Geboes K.- The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract Res Clin Gastroenterol, 2007, 21, 1089-1108.
20. McCormack PL, Keam SJ.- Bévacizumab : a review of its use in metastatic colorectal cancer. Drugs, 2008, 68, 487-506. (Pubitemid 351342019)
21. Sachdev JC, Jahanzeb M.- Evolution of bévacizumab-based therapy in the management of breast cancer. Clin Breast Cancer, 2008, 8, 402-410.
22. Miller K, Wang M, Gralow J, et al.- Paclitaxel plus bévacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 2007, 357, 2666-2676.